---
title: "Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% Downside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291195279.md"
description: "Replimune Group, Inc.'s average 12-month price target was raised to $8.17 by six analysts, up from $7.67, with forecasts ranging from $1 to $17. Based on the June 26 closing price, this implies a 30% downside. The consensus rating remains 'Hold' among eight covering analysts, comprising two buys, four holds, and two sells."
datetime: "2026-06-29T22:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291195279.md)
  - [en](https://longbridge.com/en/news/291195279.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291195279.md)
---

# Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% Downside

-   According to estimates from 6 analysts, Replimune Group, Inc. stock's average price target has risen from $7.67 to $8.17, with forecasts ranging from $1 to $17 per share
-   Based on the Jun. 26 closing price, the updated target implies approximately 30% potential downside
-   Consensus rating remains at “Hold” across 8 covering analysts, with 2 Buys, 4 Holds and 2 Sells

Explore more price target data and ratings for Replimune Group, Inc. on the , and track all previous and future analyst recommendations for Replimune Group, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [Replimune announces annual shareholder meeting](https://longbridge.com/en/news/294186963.md)
- [Replimune RP1 melanoma BLA wins favorable 10-3 FDA advisory panel vote on IGNYTE efficacy data](https://longbridge.com/en/news/294422729.md)
- [Why Replimune (REPL) Is Up 15.5% After Supportive FDA Panel Vote On IGNYTE Melanoma Data](https://longbridge.com/en/news/294586250.md)
- [Boothe Investment Group Inc. Sells 13,044 Shares of Citigroup Inc. $C](https://longbridge.com/en/news/294473355.md)
- [Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff](https://longbridge.com/en/news/294101082.md)